ArticleFuture oncology (London, England)2025
TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) program: 5-year retrospective hepatic safety assessment.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors.Cancer metastasis reviews · 2026Review
- Assessing the effectiveness of the TURALIO (pexidartinib) risk evaluation and mitigation strategy program: patient knowledge, attitudes, and behavior survey (2020-2024).Patient related outcome measures · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsTo assess hepatic safety data of pexidartinib in adult patients with tenosynovial giant cell tumor (TGCT) from the retrospective 5-year evaluation of the TURALIO® Risk Evaluation and Mitigation Strategy (tREMS) Program. PATIENTS &
methodsWe analyzed data collected from healthcare professionals, patients, pharmacies, and distributors who participated in the tREMS Program from August 2019 to June 2024.
resultsFor the current reporting period, June 2022 to June 2024, of the 524 patients enrolled in the tREMS with ≥ 1 dispense of pexidartinib, 24 (4.6%) had adverse events or laboratory abnormalities suggestive of serious and potentially fatal liver injury, with a total of 45/735 (6.1%) patients over 5 years. One (0.2%) patient in the current period had confirmed vanishing bile duct syndrome (VBDS) and was recovering at last follow-up. Another patient from the previous reporting period had unconfirmed VBDS and was alive with unknown recovery status at last follow-up. For the current reporting period and cumulative 5-year tREMS assessment, the reported frequency and pattern of liver injury were consistent with the phase 3 ENLIVEN trial.
conclusionsThe tREMS Program effectively mitigates the risk of hepatotoxicity through careful monitoring and early intervention. Pexidartinib remains a viable treatment option for TGCT when managed according to recommended guidelines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.